Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Louisville
• Treatments: Folfirinox; Gemcitabine

Criteria

Inclusion Criteria:

• greater than or equal to 18 years of age

• diagnosed with stage III pancreatic cancer

• tumor is measurable

• GFR > mL/min/1.73m2

• willing and able to comply with protocol requirements

• AST/ALT >3 times upper limit of normal

• stable surgical post-operative course as defined by operative surgeon

Exclusion Criteria:

• participating in another clinical trial for the treatment of cancer at the time of screening

• pregnant or currently breast feeding

• have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure

• have non-removable implants with metal parts within 1 cm of the target lesion

• had a myocardial infarction within 3 months prior to enrollment